Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

6
OCUL / Ocular Therapeutix, Inc. 10-Q (Quarterly Report)

2018-08-08 sec.gov
ocul_Current_Folio_June 30, 2018 Table of Contents
OCUL

55
Your Daily Pharma Scoop: Jazz Reports Mixed Bag, Roche And Takeda Positive

2018-07-23 seekingalpha
Discussion: Jazz Pharmaceuticals (JAZZ) announced publication of the pivotal Phase 3 trial of Vyexos (daunorubicin and cytarabine) liposome for injection compared to standard of care (‘SOC) cytarabine and daunorubicin (7+3) in the Journal of Clinical Oncology. Vyxeos is a fixed combination of daunorubicin and cytarabine for intravenous liposome injection available in 44/ 100 mg variants. Vyexos was approved by the FDA a year ago in August 2017.
OCUL SNGX JAZZ AGN MRK IDXG CRBP AMD LLY PFE BMY

6
Ocular Therapeutix Sees Hammer Chart Pattern: Time to Buy?

2018-07-19 zacks
Ocular Therapeutix, Inc. (OCUL - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because OCUL recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
OCUL

24
Abbott (ABT) Beats on Earnings and Revenues in Q2

2018-07-18 zacks
Abbott Laboratories (ABT - Free Report) is an Illinois-based company focused on bringing a diverse line of healthcare products to the market.
ABT OCUL JAKK FTRPR ABT FTR

17
Grupo Simec (SIM) Catches Eye: Stock Jumps 7.1%

2018-07-18 zacks
Grupo Simec, S.A.B. de C.V. (SIM - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 17.1% in the past one-month time frame.
OCUL JAKK MT FTRPR MT FTR

18
Should You Buy E*TRADE (ETFC) Ahead of Earnings?

2018-07-18 zacks
Investors are always looking for stocks that are poised to beat at earnings season E*TRADE Financial Corporation (ETFC - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
OCUL JAKK FTRPR ETFC FTR

17
Should You Buy Union Pacific (UNP) Ahead of Earnings?

2018-07-18 zacks
Investors are always looking for stocks that are poised to beat at earnings season and Union Pacific Corporation (UNP - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
OCUL JAKK FTRPR UNP FTR

17
Why Earnings Season Could Be Great for Blackstone (BX)

2018-07-18 zacks
Investors are always looking for stocks that are poised to beat at earnings season and The Blackstone Group L.P. (BX - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
OCUL JAKK FTRPR FTR

61
Luminex (LMNX) Looks Good: Stock Adds 5.7% in Session

2018-07-18 zacks
Luminex Corporation (LMNX - Free Report) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 10.9% in the past one-month time frame.
OCUL JAKK FTRPR LMNX CHEK CHEKW FTR

17
Is a Surprise Coming for Cintas (CTAS) This Earnings Season?

2018-07-18 zacks
Investors are always looking for stocks that are poised to beat at earnings season and Cintas Corporation (CTAS - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
OCUL CTAS JAKK FTRPR FTR

18
Why Skyworks Solutions (SWKS) Might Surprise This Earnings Season

2018-07-18 zacks
Investors are always looking for stocks that are poised to beat at earnings season Skyworks Solutions, Inc. (SWKS - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
OCUL SWKS JAKK FTRPR FTR

17
Why Celanese (CE) Might Surprise This Earnings Season

2018-07-18 zacks
Investors are always looking for stocks that are poised to beat at earnings season and Celanese Corporation (CE - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. That is because Celanese is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for CE in this report.
OCUL JAKK FTRPR FTR CE

17
Should You Buy Alliance Data Systems (ADS) Ahead of Earnings?

2018-07-18 zacks
Investors are always looking for stocks that are poised to beat at earnings season and Alliance Data Systems Corporation (ADS - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. That is because Alliance Data Systems is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat.
OCUL JAKK FTRPR ADS FTR

OCUL : Ocular Therapeutix Stock Analysis and Research Report

2017-10-19 - Asif

Ocular Therapeutix is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its bioresorbable hydrogel-based drug product candidates are designed to provide extended delivery of therapeutic agents to the eye. Its lead product candidates are DEXTENZA (dexamethasone insert), for the treatment of post-surgical ocular inflammation and pain, allergic conjunctivitis and dry eye disease, and OTX-TP, for the treatment of glaucoma and ocular hypertension, which are extended-delivery, drug-eluting inserts that are placed into the canaliculus through a natural opening called the punctum located in the inner portion of the eyelid near the nose. Its intracanalicular inserts combine its hydrogel technology with U.S. Food and Drug Administration, or FDA, approved therapeutic agents with the goal of providing extended delivery of drug to the eye. Ocular also has...

Related Articles

RNVA: Rennova Health Analysis and Research Report

7h - Asif

Business overview Rennova Health, Inc. (together with its subsidiaries, “Rennova”, “we” or the “Company”) is a provider of an expanding group of health care services for healthcare providers, patients and individuals. Beginning in 2018, the Company intends to focus on and operate two synergistic divisions: 1) Clinical diagnostics through its clinical laboratories; and 2) Hospital operations through its Big South Fork Medical Center, which opened on August 8, 2017, and a hospital in Jamestown Tennessee, including a doctor’s practice, the assets of which the company expect to acquire in the second quarter of 2018, pursuant to the terms of a definitive asset purchase agreement that the company entered into on January 31, 2018, as more fully discussed below. The company believe that its approach will produce a more sustainable business model and the capture of multiple revenue streams from medical providers, patients and hospital services. Management determined that because Big So...

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

CUSIP: 67576A100